Chi-Med (HCM) may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company. "We have been operating for 16 years and we have a cash generative commercial business in China to help fund innovation," said Chi-Med's CEO Christian Hogg. "We are not a binary biotech." Chi-Med is focused on developing drugs to treat cancer and auto-immune disease with seven drug candidates in 25 active clinical trials. It also has an enormous commercial business in China selling over the counter drugs. Chi-Med is partnering with the likes of AstraZeneca (AZN) , Eli Lilly (LLY) and Nestle Health Sciences to provide finance and expertise to support the development of its business. At the end of the first half of the year, Chi-Med had received $118.5 million in income from its partners.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.